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Abstract
Background: Given that tremor is one of the most prevalent and disabling features of multiple sclerosis (MS), we will review the most significant milestones in
tremor in this disease in recent years, focusing on prevalence, clinical features, anatomical basis, and treatment.
Methods: Data for this review were identified by searching MEDLINE with the search terms ‘‘multiple sclerosis’’ and ‘‘tremor’’. References were also identified
from relevant articles published between January 1966 and May 2012.
Results: The predominant type of MS tremor is a large-amplitude, postural, and kinetic tremor, which most commonly affects the arms, although tremor can also
involve head, neck, vocal cords, and trunk. Involvement of the tongue, jaw, or palate has not been reported. Although the anatomical basis underlying tremor in MS
is poorly understood, the link between the cerebellum and the MS-related tremor is supported by clinical and experimental studies. Currently available medication
is often unsuccessful in most cases. Surgical treatment can be a satisfactory alternative to treat severe and disabling tremor.
Discussion: Tremor in MS patients could be considered as an advanced consequence of the disease and its presence suggests a more aggressive course. MS tremor
can be severe and very disabling for a small group of patients. Treatment of MS tremor remains a great challenge. Recent studies suggest that dissociating tremor
from cerebellar dysfunction using selected clinical tests would be the key issue to successful surgical treatment. Understanding the pathophysiology and biochemistry
of tremor production in MS may lead to new therapeutic approaches.
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Introduction
Tremor is an involuntary, rhythmic, muscle movement involving
oscillations of one or more parts of the body, resulting from repeated
contraction and relaxation of opposing muscle groups.1–3 Multiple
sclerosis (MS) is a common chronic inflammatory disease of the central
nervous system; it most frequently appears in early adulthood.4–6
Action tremor was for a long time considered to be a common feature
of MS. In fact, the French neurologist Jean-Martin Charcot described
tremor as one of the defining features of MS, together with nystagmus,
and scanning speech.7
Given that tremor is one of the most prevalent and disabling
features of MS,8 we will describe the most significant recent milestones
that relate to MS tremor, focusing on prevalence, clinical features,
anatomical basis, and treatment.
Review criteria
Data for this review were identified by searching MEDLINE (in
May 2012) with the search terms ‘‘multiple sclerosis’’ and ‘‘tremor’’.
References were also identified from relevant articles published
between January 1966 and May 2012.
Prevalence of tremor in multiple sclerosis
Studies have provided estimates of the prevalence of tremor in the
MS population that range widely, between 25% and 58% (Table 1).8
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In a 3-year-follow up study, Weinshenker et al.9 reported that
cerebellar deficits of functional importance were present in one-third
of 259 MS patients. Two more recent studies have assessed the
prevalence of tremor in MS.10,11 Alusi et al. 10 described upper limb
tremor in 58% of 100 patients randomly selected from a London MS
unit. The tremor was minimal in 27%, mild in 16%, and moderate to
severe in 15% of patients.10 However, as that study was conducted
from a specialty clinic, the relatively high prevalence and severity of
tremor might be due to selection bias. In a community-based study
involving 200 MS patients in Olmsted County, Minnesota, Pittock
et al.11 noted tremor in 25.5% of patients, and severe tremor in 3% of
patients. This community-based study probably provides a more
realistic estimate of the prevalence of MS-related tremor.
Despite these estimated figures, the prevalence of tremor in MS
remains very difficult to establish accurately for three reasons. First,
because of the complex natural history of MS, there is a transience of
neurological signs, which may occur only during the relapsing and
remitting phase of the disease. Second, there is the problem of
distinguishing intention tremor from dysmetria.12 Finally, the Kurtzke
Expanded Disability Status Scale (EDSS),13 the gold standard in
assessing physical disability in MS, does not assess tremor.
Clinical features
Tremor is defined as a rhythmical, involuntary oscillatory move-
ment of a body part14 and can be classified according to the consensus
statement of the Movement Disorder Society.14 Tremor at rest is
separated from action tremor, which is produced by voluntary muscle
contraction. Action tremor includes postural, isometric, and kinetic
tremors, and the last form includes intention tremor.14
MS tremor is manifested on action as postural tremor (tremor
present while voluntarily maintaining a position against gravity) and/
or intention tremor (occurring during target-directed movement where
tremor amplitude increases during visually guided movements towards
the target).15 MS tremor typically involves the upper limbs, although
tremor can also involve head, neck, vocal cords, and trunk.15
Involvement of the tongue, jaw or palate has not been reported.15
In the two main prevalence studies,10,11 tremor was most commonly
found in the arms. According to the study by Alusi et al.10 the body
parts affected by tremor varied among the patients, with the most
common pattern being bilateral arm involvement (36 patients)
followed by unilateral arm tremor (nine patients) and tremor of the
head and arms (five patients). In every case, tremor was of an action
type (postural, kinetic, or both).10
Titubation is defined as nodding head tremor with a frequency of
3–4 Hz and may be seen in midline cerebellar disease.16 This type of
tremor can occur in isolation or combined with a postural tremor
elsewhere, especially in the arms.16 Titubation can be seen in 9% of
the MS patients.10
True rest tremor (tremor present in a body part that is not
voluntarily activated and is completely supported against gravity) and
Holmes (or ‘‘rubral’’) tremor are extremely uncommon in patients
with MS. Rest tremor was observed only in 1% of the MS patients
from the Olmsted County survey,11 whereas Holmes tremor has not
been encountered in recent prevalence studies.10,11 Task-specific
tremors (for example, primary writing tremor) have not been
documented in MS.10,11 Similarly, simple kinetic tremor, which occurs
during voluntary non-target-directed actions—for example, opening
and closing a fist—has not been observed in MS patients in these
studies.10,11
Despite the fact that the basal ganglia are relatively frequently
involved by MS plaques17 and that almost any neurological symptom
or sign can appear with the disease, movement disorders other than
tremor are quite uncommon in MS. Moreover, movement disorders
can be observed in patients with MS in the absence of basal ganglia
involvement.18 Tranchant et al.,18 in the largest review of movement
disorders in MS, concluded that paroxysmal dystonias, ballism,
chorea, and palatal myoclonus could be caused by demyelinating
lesions, whereas parkinsonism, dystonia, and other types of myoclonus
often seemed to be coincidental.
Anatomical basis
The anatomical basis underlying tremor in MS is poorly under-
stood, mostly because MS is a multifocal disease, and therefore tremor
occurrence often cannot be directly linked to a specific neuroanato-
mical lesion.15
The link between the cerebellum and the MS-related tremor is
supported by clinical and experimental studies. In MS patients, tremor
severity has correlated with the degree of dysarthria, dysmetria, and
dysdiadochokinesia.10 However, no correlation was found between
the severity of tremor and cognitive function, the Barthel disability
profile, or grip strength, which provides strong evidence to support
a specific defective cerebellar function rather than just with diffuse
cerebral damage.10 In addition, the high occurrence of bilateral,
symmetrical tremor may be explained by the presence of multifocal
damage to the cerebellum and its connections.8 Several animal studies
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have been undertaken to help understand the anatomical structures
involved in the production of MS tremor.19 Experimental studies from
the 1930s showed that transection of the superior cerebellar peduncle
caused intention tremor in monkeys.19 This is consistent with the case
described by Nakamura et al.,20 who, using magnetic resonance
imaging (MRI) in a single case, showed that a plaque in the superior
cerebellar peduncle resulted in severe postural tremor. Additionally,
intention tremor can also be induced by reversible cooling of the
dentate nucleus (the origin of most cerebellar efferents) in monkeys.19
Interestingly, Carpenter and Hanna 21 reported that tremor induced
by transection of the superior cerebellar peduncle can be diminished
by a second lesion in the lateroventral or centromedian thalamus.
Taken together, these results strongly suggest that damage to
cerebellar efferents (through lesions of the dentate nucleus or superior
cerebellar peduncle) may cause disinhibition of thalamic nuclei,
which are the main producers of intention tremor. The findings of
these primate experiments are supported by newer MRI and/or
pathological studies that have further studied the involvement of the
cerebellum in MS patients.22–26
Cerebellar grey matter atrophy appears to be more prominent and
clinically relevant than white matter atrophy.25 This cerebellar grey
matter damage has been associated with clinical cerebellar dysfunc-
tion, including patients who have presented with clinically isolated
syndromes.27 A pathological study of Kutzelnigg et al.26 found
widespread demyelination in the cerebellar cortex in patients with
MS, which was more pronounced in patients with progressive disease
than those with the relapsing–remitting form. Furthermore, the
authors suggested that this cerebellar demyelination may be more
prominent than that seen in the cerebrum.26
The absence of rest tremor argues against an involvement of the
basal ganglia in the production of MS tremor. However, there are
some data which suggest that cerebellar tremors seen in MS might
actually be generated by the basal ganglia. Foote et al. 28 reported
the satisfactory results in one patient with MS tremor who underwent
placement of two thalamic deep brain stimulation (DBS) electrodes
(one at the ventralis intermedius nucleus (VIM)/ventralis oralis
posterior nucleus border and one at the ventralis oralis anterior/
ventralis oralis posterior border). Ventralis oralis posterior is known
to be the basal ganglia output nucleus.28
In the 1980s, several studies showed the susceptibility of cerebellar
tremor amplitude and frequency to peripheral factors, such as
mechanical loads, which implied the involvement of stretch-elicited
peripheral feedback mechanisms in the manifestation of cerebellar
tremor.29,30 Hence, cerebellar tremor is thought to be modulated
through increased long latency stretch reflexes.31 In support of this
view, load-compensating tasks, evoking sudden stretch, induced an
increase in tremor in cerebellar patients.32
On the other hand, MS intention tremor may be modulated by
sensory information.33 This supports the notion that the cerebellum is
involved in the production of tremor because the proprioceptive
information about the direction, velocity, and amplitude of movements
is mainly generated by muscle spindles, and additionally by tendon
organs, joint, and cutaneous receptors, and enters into the cerebellum
via the spinocerebellar pathway.33
Patients with cerebellar deficits show a specific difficulty in using
visual information to control arm and hand movements.34,35 In the
study of Feys et al.36 movement accuracy during slow wrist tracking
tasks decreased significantly more in MS patients with tremor than in
healthy controls when visual feedback was absent, which is consistent
with prior studies.37 Feys et al.36 postulated that tremor amplitude
could specifically relate to deficits in online proprioceptive processing,
leading to an increased visual dependence during sensorimotor tasks.
The excitability of muscle spindles,38–40 which are an essential part
of the reflex loop, and the velocity of peripheral nerve conduction are
temperature dependent.41 Thus, decreasing the stretch sensitivity of
the muscle spindles and therefore also the long latency stretch reflexes,
by means of cooling, may have an important effect on tremor.41 In
line with this assumption, several studies have manipulated the sensory
input to the central nervous system.42–44 A reduction of cerebellar
tremor during handwriting has been found after the application of an
ischemic block to the arm.42 In two additional experimental studies,
cooling of the arms markedly reduced intention tremor severity in
patients with MS.43,44 Moreover, the effect on tremor seemed to be
proportional to the intensity of the cooling.44 Feys et al.44 argue that
this effect might have been partly due to decreased muscle spindle
function and decreased nerve conduction velocity, which in turn
resulted in decreased sensory input into tremor producing cerebellar
circuits. In contrast, overall tremor amplitude increased during
memory-guided movements when muscle spindles were artificially
activated by means of tendon vibration.45 Following previous data
suggesting that MS intention tremor is modulated by sensory
information, Feys et al.46 have recently studied the contribution of
peripheral reflexes to the generation of MS intention tremor by
measuring tendon reflexes, demonstrating that MS patients with
tremor have a greater latency of brachioradialis, biceps, and triceps
tendon reflexes than healthy controls and MS patients without tremor.
In summary, clinical observation as well as animal and experimental
studies strongly point to the cerebellum and its connections as the
major source of intention tremor production, but further research is
needed to better understand the pathophysiologic model underlying
the production of tremor in MS.
Assessment of tremor in multiple sclerosis
In MS tremor, a valid, precise, and reliable scale is required if the
efficacy of different interventions is to be assessed accurately. More-
over, it would ideally take into account the ataxic elements, which
usually complicate the clinical picture. Most tremor rating scales
deployed in therapeutic trials involving patients with MS have not
been tested for their reliability and sensitivity.47–49
There are only two published studies examining the reliability of a
clinical scale for scoring tremor in MS.50,51 Hooper et al.50 developed
a modified version of the Fahn–Tolosa–Marin Tremor Rating Scale52
to accommodate goal-directed tremor and studied its reliability in
patients with MS. However, they failed to assess the validity of the
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scale.50 Alusi et al.51 examined the validity and comparative reliability
of the 0–10 tremor severity scale devised by Bain et al.,53 which had
already been validated in other tremulous conditions. The authors
concluded that this scale represents a valid and reliable way of
assessing tremor in these patients.51 The most reliable test was shown
to be scoring tremor on posture, whereas kinetic tremor and asso-
ciated ataxic deficits were more difficult to score reliably.51 Despite
its reliability, the scale has so far only been used in a few clinical
studies.10,54,55
Outcome of tremor in multiple sclerosis
According to Alusi et al.,10 the median latency from disease onset to
the development of tremor is 11 years. Hence, tremor in MS patients
could be considered as an advanced consequence of the disease.
Patients who exhibit clinical signs of cerebellar damage early in
the disease course tend to develop severe disability more quickly.56
Although in the majority of MS patients the severity of the tremor is
mild, tremor can be severe and very disabling for a small group of
patients.10 In the two main prevalence studies,10,11 tremor was
associated with greater disability. The study of Alusi et al.10 showed
that 27% of the patients had tremor-related disability and 10% had
incapacitating tremor. Moreover, patients with severe tremor were
more likely than those without tremor to be wheelchair dependent and
have a worse EDSS.10 In the Olmsted County study, patients with
tremor of any severity were more likely to be unemployed or to have
retired early because of disability, and they had on average a 2-point
higher EDSS.11 Other studies have shown that intention tremor
severity seriously affects many activities of daily living, such as
drinking, handwriting, or personal computer interaction.57,58
Treatment
General considerations
As with other chronic diseases, it is important to consider the
psychological and social impact of illness on patients. MS patients
may be unable to continue full-time work, and financial problems
may rise. Physicians should coordinate care with other healthcare
professionals in order to address these social and psychological issues.
The impact of the disease on the patient’s family should also be taken
into account. It may be beneficial for MS patients to bring their spouse
or partner to a consultation, to help them better understand the disease
and to discuss their difficulties and concerns.
Patient-centered associations may be of help in offering individual
and group support, education and advice. Through such interactions,
patients may benefit by learning ways to cope with the many practical
day-to-day difficulties that arise for those living with this disease.
There are physical aids as well as certain lifestyle changes that may
be helpful in patients with mild tremor. Electromagnetic fields, limb
cooling, physiotherapy, weight bracelets, orthoses, and specialized
software may offer some symptomatic relief. For example, physiother-
apeutic approaches, such as arm cooling, appear to reduce tremor
severity.44,59 The effect of peripheral sustained cooling on intention
tremor was first described by Albretch et al.;59 in their study, patients
achieved significantly better results on a clinical testing battery after
sustained cooling of the tremulous forearm in ice water. In a similar
study, Feys et al.44 described a clear reduction of overall tremor
amplitude and frequency during the step-tracking task after two
different intensities of sustained cooling of the arm. Although the
effects of cooling on intention tremor are probably temporary, both
studies showed that they persist for at least 30 minutes.44,59 This
sustained benefit led the authors to argue that cooling of the arm may
be useful before performing activities of daily life, such as applying
make-up, eating a meal, or writing and signing documents.44,59
Reduction of intention and postural tremor in three MS patients
was achieved with pulsed electromagnetic fields,60 although further
trials are needed to support this finding.
The use of a mouse-driven computer system was evaluated by Feys
et al.58 These researchers found significant improvement in the time
needed to complete some basic mouse-driven computer operations
using specialized software developed to aid computer use in 36
tremulous MS patients included in their study.58 Furthermore, some
patients may experience modest benefits from relaxation methods
aimed at alleviating the anxiety or stress that may exacerbate tremor.
Lifestyle changes may be of benefit in some patients. These changes
include restricting caffeine intake or other stimulants that may increase
symptoms.
Although there is no cure for tremor in MS, several therapies can
ease the condition for some patients (Table 2). The issue is that such
treatments for tremor in MS have side effects, and it is important to
carefully consider in each patient whether the benefits outweigh any
side effects. Medications should be used to reduce functional disability
or embarrassment and to improve health-related quality of life.61,62
Hence, treatment generally begins when the tremor begins to interfere
with the patient’s ability to perform daily activities, or if the tremor
is embarrassing to the patient. Surgery should be limited to those
disabling cases that fail to benefit from several different medications.
Pharmacological agents
Tremor in MS patients is difficult to manage and often frustrat-
ing because drug treatment with currently available medication is
unsuccessful in most cases. Some clinical relief has been reported for
a range of drugs, including primidone,63 gluthetimide,64 intrathecal
baclofen,65 and isoniazid.66 However, most of the published literature
on medical treatment consists of case reports and uncontrolled open
label studies characterized by small patient size and short duration
of drug intake.8 Some functional relief was noticed with glutethimide,
an hypnotic-sedative drug ,in six of eight tremulous MS patients
included in an open label study.64 Weiss et al.65 reported an alleviation
of tremor with intrathecal baclofen in a single patient with bilateral
arm tremor. The tremor amplitude decreased nearly linearly with
increasing intrathecal baclofen dosage, and disappeared completely at
a dose of 250 mg/day.65
Controlled clinical trials have been published on the use of pro-
pranolol,47 ethanol,47 isoniazid,47,67,68 carbamazepine,49 ondansetron
(5-hydroxytryptamine type 3 receptor antagonist),69 dolasetron,70 and
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levetiracetam.71 Koller et al.47 evaluated the effect of propranolol,
isoniazid and ethanol on tremor in three tremulous MS patients in a
double blind crossover trial and did not find beneficial effect for any of
the treatments. Although no further trials with propranolol have been
published, it should be emphasized that two tremulous MS patients
were excluded from a thalamotomy trial because they had achieved
functional improvement after propranolol use.54
Two double-blind placebo-controlled trials using isoniazid have
been published.67,68 In the first study, alleviation of tremor was
achieved in six of eight patients,67 assessing functional improvement in
four of them. In the second study, measurable tremor reduction was
achieved in all six patients, although no functional improvement was
noticed.68 Despite this clinical improvement, doses of isoniazid used to
treat MS-related tremor are usually very high (up to 1200 mg a day)
and consequently this may lead to significant adverse effects such as
anorexia, nausea,72 drowsiness, dysphagia, and increased bronchial
secretions.73,74
A successful improvement of tremor was found in seven patients in
a small single-blind placebo-controlled trial with carbamazepine.49
However, no functional improvement was mentioned.49 In a placebo-
controlled, double-blind, crossover study using a single intravenous
dose of ondansetron, tremor reduction was described in 12 of the 16
tremulous MS patients, with functional improvement in nine of
them.69 However, no positive effects were described in another study
using the same intervention and doses.75 In the same way, a newer
small clinical trial has failed to show beneficial effects on cerebellar
ataxia with dolasetron, another 5-HT3 receptor antagonist.70
Despite the growing interest in cannabis as a possible therapeutic
agent in MS, no positive effect has been found in several well-
conducted randomized controlled trials with orally administered
cannabis extracts76–78 or oral D9-tetrahydrocannabinol.76
Levetiracetam, which has been suggested to have beneficial effects
on cortical myoclonus or post-ischemic Holmes’ tremor,79–81 appeared
effective for cerebellar tremor in both a case series study and an open-
label trial with tremulous MS patients. Likewise, a crossover study
showed a modification of kinematic parameters although without
functional improvement in most of the six MS tremulous patients
included.82 However, a randomized, placebo-controlled, double-blind,
crossover study neither found a significant decrease in tremor severity
nor an improvement in functionality in 14 patients with MS-related
tremor.71 Therefore, the clinical relevance of levetiracetam in the
treatment of MS tremor remains unclear.
Topiramate may be a new therapeutic option to treat cerebellar
tremor and ataxia in patients with MS.83–85 A small, open-label study
of topiramate in patients with cerebellar tremor showed improvement
in clinical and electrophysiological indices of limb tremor.83 The
authors hypothesized a net inhibitory effect on the cerebello-thalamo-
cortical pathways due to facilitation of gamma-aminobutyric acid
(GABA)ergic transmission, and antagonism at the AMPA/kainate
receptor.83 Similarly, topiramate have been reported to provide relief
in cerebellar signs in two recent case reports.84,85
More recently, a pilot trial with riluzole suggested benefits in
patients with cerebellar tremor.86 Alternatively, Chansakul et al.87
reported a dramatic resolution of head tremor with rituximab. These
newer studies postulate that aggressive treatments should be con-
sidered in the presence of a recently developed tremor secondary to
MS.
Recently, in a study of 23 MS patients with tremor, there was a
significant improvement after botulinum toxin compared with that
after placebo treatment in the Bain score for tremor severity at 6 weeks
(p50.0005) and 12 weeks (p50.0001), writing at 6 weeks (p50.0001)
and 12 weeks (p50.0003), and Archimedes spiral drawing at 6 weeks
(p50.0006) and 12 weeks (p50.0002).88 This study provides Class III
evidence that targeted injection of botulinum toxin type A is associated
with significant improvement in MS-related upper limb tremor.88
Surgical treatment
Advances in surgical interventions offer patients an alternative
treatment modality when pharmacotherapy is inadequate. The
surgical treatment options for tremor in MS are stereotactic
thalamotomy and DBS, which both can be a satisfactory alternative
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to treat severe and disabling tremor. In the majority of the reported
cases, the surgical target for DBS implantation is the VIM.
Stereotactic thalamotomy has been performed for the alleviation of
MS tremor since 1960.89 More recently, thalamic DBS has been
deployed effectively. Although Niranjan et al.90 described marked
improvement of tremor in all three tremulous MS patients using
gamma-knife thalamotomy, no further studies have been published to
evaluate this non-invasive alternative. There are three trials in which
thalamotomy and DBS have been compared in MS patients.55,91,92
Schuurman et al.91 did not find significant differences between
thalamotomy and DBS in functional outcome for a subgroup of MS
patients. In a non-randomized study conducted by Bittar et al.,55
thalamotomy was a more efficacious surgical treatment for intractable
MS tremor (78% tremor reduction for postural tremor and 72% for
intention tremor) than the DBS group (64% tremor reduction for
postural tremor and 36% for intention tremor) after a mean follow-up
period of 15–16 months. However, the incidence of persistent
neurological deficits was also higher in patients receiving lesional
surgery.55 In a more recently study, Yap et al.92 concluded that both
thalamotomy and thalamic DBS were comparable procedures for
tremor suppression and that adverse effects occurred with both
procedures. Although larger clinical trials comparing both interven-
tions are needed, currently DBS is widely accepted as the preferred
surgical strategy.
Lack of objective measurements of tremor in MS and post-surgical
efficacy are the main reasons that may explain why VIM DBS has
not been established yet as a recommended general therapeutical
option.54,93–95 Although sophisticated tools and mathematic models
have been created to make pre-surgical qualification and post-surgical
evaluation more objective, they have not been widely accepted, mostly
because of their complexity and poor standardization.53,91–93 Further-
more, the possibility of progression of the disease makes the objective
evaluation of the surgery even more difficult. This may explain
conflicting results. Indeed, older studies suggest a disappointing
prognosis with progressive disability in most patients;96,97 however, a
recent DBS study reported 5-year permanent tremor relief.98
In MS tremor, there is a variable contribution of ataxia to the
overall tremor phenotype.37,99 Ataxic tremor responds poorly to both
stimulation and lesioning, which may explain why MS tremor
responds so variably to stimulation. According to many authors,
dissociating tremor from cerebellar dysfunction using selected clinical
tests would be the key issue to successful treatment.93,94,100 In line with
this assumption, in a recent prospective study Hosseini et al.101 have
confirmed the higher efficacy of VIM DBS treatment of kinetic tremor
in the subgroup of MS patients with minor or absent cerebellar
dysfunction.
It has been observed that tremor in MS can sometimes permanently
decrease during the course of DBS.102 This permanent tremor
reduction has been attributed to limb weakness (occurring with MS
progression) preventing the expression of tremor.102
Although a review of the reported cases suggests that chronic DBS
produces improved tremor control in MS,103 it should be emphasized
that most of the studies are small observational retrospective studies
with predominantly short-term follow-up (1 year or less) and with a
remarkable absence of standardized outcome measures or information
on long-term functional outcome.103,104
It is interesting to note the recent study of Hassan et al.105 reported a
prospective 12-year follow-up of a cohort of nine patients with MS
tremor, previously reported by Matsumoto and coworkers.106 The
study showed that the benefit of surgery (six patients underwent
thalamotomy and three DBS) was overall short lived (median 3
months), with long-term poor prognosis.105 Moreover, over half of the
patients were dead by 7 years and survivors were severely impaired,
which led the authors to conclude that when surgery is considered for
MS, patients have already entered a disease trajectory with dismal
prognosis. This contrasts with prior studies suggesting EDSS stability
at 12–36 month follow-up.107,108
In summary, although the majority of published studies suggest
a tremor reduction in almost all patients immediately after surgery,
the short-term follow-up of the published series is insufficient to
conclude whether surgery is a judicious strategy. Nonetheless, the
5-year permanent tremor reduction reported in a recent DBS study98
encourages the pursuit of further DBS trials.
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